Verona Pharma VRNA has signed a definitive agreement with pharma bigwig Merck MRK. Per the terms, the pharma giant will ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Asthma treatment in the UK has until recently relied heavily on a strategy of regular ‘maintenance’ inhaled corticosteroid (ICS) and separate ‘reliever’ inhalers containing short-acting beta-agonist ...

Serine-/Cysteine-Based sp2-Iminoglycolipids as Novel TLR4 Agonists: Evaluation of Their Adjuvancy and Immunotherapeutic Properties in a Murine Model of Asthma Manuel González-Cuesta ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to a new study. Although its efficacy hasn't yet been tested in humans, the ...

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...

Boxed warnings indicating the increased mortality risk from long-acting beta-agonists like vilanterol in people with asthma may be seen on the packaging for medications including Trelegy Ellipta, ...

Importance The role of intravenous short-acting beta-2 agonist (SABA) in acute asthma in childhood is unclear. Objectives To assess the safety and efficacy of intravenous SABA versus placebo for acute ...

This new pill works by triggering the metabolism in the muscles, activating them to burn more fat, without the gastrointestinal side effects of weight loss jabs ...

MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight ...

Medical experts are dismayed over a federal report’s claim that kids are overprescribed asthma medications, saying it minimizes how many lives the drugs save.